G Sachs issued a positive analyst rating for SBP GROUP due to its agreement with GlaxoSmithKline to obtain exclusive commercialization rights for bepirovirsen in China, a promising therapy for chronic hepatitis B. The broker believes SBP GROUP's extensive experience, strong sales force, and established network make it an ideal partner for this drug, which is expected to significantly enhance its product portfolio and drive earnings growth. Consequently, G Sachs raised its earnings forecasts and increased the target price for the stock.
